Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy?
Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy?
复制标题
DOI：
10.1038/bjc.1989.192
复制
发表时间：
1989-06
影响因子：
8.8
通讯作者：
Ritter, M A
中科院分区：
文献类型：
--
作者：
Al Jabaari, B;Ladyman, H M;Larche, M;Sivolapenko, G B;Epenetos, A A;Ritter, M A
使用单克隆抗体 MR6（被认为与白细胞介素 4 生长因子受体 (IL-4R) 结合）的研究表明，IL-4R 分子在上皮来源的肿瘤中上调，并且放射性标记的 MR6 作为体内肿瘤成像剂是有效的。使用单克隆抗体 MR6 对多种实体瘤进行的免疫组织化学分析表明，多种癌症中 IL-4R 的表达升高。同等的正常组织显示该分子的表达较弱或不表达。研究的其他肿瘤均未呈阳性。肿瘤细胞上受体的分子量与正常组织上的受体的分子量无法区分。这些数据提出了这样的可能性：IL-4R是一种新癌基因的产物，因此这种生长因子受体的表达升高可能参与癌发生过程。因此，IL-4R 的单克隆抗体（例如 MR6）不仅可用于诊断和免疫闪烁扫描，而且还可用于上皮癌的体内抗体引导治疗。
Studies using monoclonal antibody MR6, which is thought to bind to the interleukin-4 growth factor receptor (IL-4R), indicate that IL-4R molecules are upregulated in tumours of epithelial origin and that radiolabelled MR6 is effective as an in vivo tumour imaging agent. Immunohistochemical analysis of a wide range of solid tumours using monoclonal antibody MR6 has demonstrated elevated expression of the IL-4R on a variety of carcinomas. The equivalent normal tissue showed either weak or no expression of this molecule. No other tumours studied were positive. The molecular weight of the receptor on tumour cells was indistinguishable from that on normal tissue. These data raise the possibility that the IL-4R is the product of a novel oncogene such that elevated expression of this growth factor receptor could be involved in the process of carcinogenesis. Monoclonal antibodies to the IL-4R, such as MR6, may therefore be useful reagents not only for diagnosis and immunoscintigraphy, but also for in vivo antibody-guided therapy of epithelial cancers.